Digmbio secures KRW 12 billion in series A funding to boost development of anticancer and 카지노 슬롯 머신 규칙 disease treatments

[by Kang, In Hyo] Amid the broader decline in pharmaceutical and biotech investments due to interest rate hikes and macroeconomic uncertainties, a Korean novel drug 카지노 슬롯 머신 규칙 company has recently secured a large-scale investment.

Digmbio, a biotechnology company specializing in novel drug 카지노 슬롯 머신 규칙, announced on March 25 that it has successfully secured KRW 12 billion (approximately USD 8.1 million) in Series A funding. The investment round saw participation from Partners Investment, Meritz Securities, Samho Green Investment, Industrial Bank of Korea, Medytox Venture Investment, Cornerstone Investment Partners, and Myriad Life Sciences.

With this investment, Digmbio plans to prioritize completing Phase 1 clinical trials for its main pipeline, the next-generation targeted anticancer drug candidate ‘DM5167’ (development code). The company also aims to begin the nonclinical toxicity testing for its degenerative 카지노 슬롯 머신 규칙 disease treatment candidate, ‘DM3159’.

DM5167 is a second-generation targeted anticancer drug that selectively inhibits PARP-1. According to the company, the drug candidate effectively addresses the ‘blood toxicity’ that was a major limitation of existing first-generation PARP inhibitors. Notably, DM5167 is drawing attention as a potential treatment for patients with ‘metastatic 카지노 슬롯 머신 규칙 tumors’ associated with BRCA mutations due to its exceptional ability to cross the blood-카지노 슬롯 머신 규칙 barrier.

Currently, phase 1 clinical trial of DM5167 is underway at several institutions, including Seoul National University Hospital, Seoul National University Bundang Hospital, Samsung Medical Center, and Severance Hospital. Part 1 of the trial will evaluate the safety and tolerability of the drug in patients with HRD mutations, including BRCA1/2. Part 2 will assess the therapeutic effects by expanding the study to include patients with HRD mutation-related metastatic 카지노 슬롯 머신 규칙 tumors. In October 2024, DM5167 was selected as a Phase 1 clinical trial support project by the Korea Drug Development Fund (KDDF), securing research and development funding.

DM3159 is an innovative treatment candidate for degenerative 카지노 슬롯 머신 규칙 disease that targets the taste receptor ‘TASR GPCR’. Its mechanism of action differs from that of existing therapies, and it has demonstrated neuron protection and regeneration effects across various degenerative 카지노 슬롯 머신 규칙 disease models, including Alzheimer’s disease.

The company highlighted that a significant improvement in cognitive function was observed in the Morris water maze animal behavioral test using the 3xTG dementia animal model, which is commonly used for Alzheimer’s disease research. The company emphasized that it is actively enhancing its global competitiveness as a next-generation treatment for degenerative 카지노 슬롯 머신 규칙 diseases by conducting scale-up research in preparation for nonclinical toxicity testing.

“In a period where the biotechnology market has been shrinking over the past several years, the successful completion of this Series A funding reflects the high expectations for our company’s research achievements and future growth potential,” said Kim Jeong-min, CEO of Digmbio. “In particular, our anticancer and degenerative 카지노 슬롯 머신 규칙 disease treatment candidates already demonstrate global competitiveness and are attracting significant interest from numerous global pharmaceutical and biotechnology firms.”

“Our company’s research and 카지노 슬롯 머신 규칙 (R&D) projects are recognized for their high scientific excellence and technological differentiation, having received national new drug R&D support from the Korea Drug 카지노 슬롯 머신 규칙 Fund (KDDF), the Korea Dementia Research Center (KDRC), and the Korea Techn Incubation Program for Startup (TIPS) backed by private investment,” Kim further added. “With this investment as a starting point, we will strengthen our company’s position on the global stage.”